{"id":10217,"date":"2020-05-21T12:24:18","date_gmt":"2020-05-21T10:24:18","guid":{"rendered":"https:\/\/idibell.cat\/en\/?page_id=10217"},"modified":"2024-09-03T13:38:45","modified_gmt":"2024-09-03T11:38:45","slug":"pancreas-regeneration-pancreatic-progenitors-and-their-niche","status":"publish","type":"page","link":"https:\/\/idibell.cat\/en\/research\/area-medicina-regenerativa-english\/regenerative-medicine-program\/pancreas-regeneration-pancreatic-progenitors-and-their-niche\/","title":{"rendered":"Pancreas regeneration: pancreatic progenitors and their niche"},"content":{"rendered":"\n

\n\t\tPancreas regeneration: pancreatic progenitors and their niche\n\t<\/h1>\n

\n\t\tSummary\n\t<\/h3>\n\t

Type 1 diabetes is caused by an autoimmune destruction of pancreatic \u03b2 cells. These cells are the source of insulin, a hormone required for the regulation of blood glucose levels. One approach to recovering glucose homeostasis would be to induce restoration of \u03b2-cell mass, either by replacement with exogenous cells or by regeneration from endogenous progenitors, but the existence of such progenitors is still controversial. Rovira’s group is focused in the role of ductal cells as pancreatic progenitors in order to develop new therapies for diabetes treatment. On the other hand the lab is also studying the niche required for pancreatic progenitor maintenance.<\/p>\n

22<\/h2>\n

Publications<\/h2>\n\t\t\t\t\"Pancreas-regeneration-pancreatic-progenitors-and-their-niche\"\n\t\t\t\t\tStrategic lines<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t

To develop therapies to maintain normoglicemia in diabetic patients to avoid or reduce T1D complications.<\/p>\n

To develop regenerative therapies in human diabetes, either through manipulation of pancreatic exocrine tissue from donors in vitro, and their subsequent transplantation, or through in vivo or in vitro manipulation of patients’ pancreatic duct cells.<\/p>\n\t\t\t\t\tSelected Publications<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t